RLMD logo

RLMDRelmada Therapeutics Inc

$6.26
$0.11
(1.75%)
Today
Closed $6.38
$0.12
(1.88%)
After Hours
Updated: 07:38 PM EDT
Reported EarningsMay 12
Mkt Cap$657.66M
Vol1.46M
News
all
press releases
Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call
read more...
Benzinga
News Placeholder
More News
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High - Time to Buy?
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High - Should You Buy...
MarketBeat
News Placeholder
Relmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on Monday
Relmada Therapeutics (NASDAQ:RLMD) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-relmada-therapeutics-inc-stock...
MarketBeat
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3% - Here's What Happened
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 4.3% - What's Next...
MarketBeat
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 6,042,204 shares, an increase of 61.9% from the March 15th total of 3,731,201 shares. Currently, 7.3% of the company's stock...
MarketBeat
News Placeholder
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month High - Should You Buy?
Relmada Therapeutics (NASDAQ:RLMD) Sets New 12-Month High - Here's What Happened...
MarketBeat
News Placeholder
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.
Zacks
News Placeholder
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Zacks
News Placeholder
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
<
1
2
...
>

Advertisement|Remove ads.